InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,576.98
(
0.07%
)
US TECH 100
19,930.80
(
0.19%
)
Dow Jones
39,291.97
(
-0.13%
)
Brent Oil
84.50
(
-0.24%
)
Bitcoin
57,521.28
(
-0.86%
)
Post# of 252540
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120006
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 116643

Friday, 03/18/2011 2:22:44 PM

Friday, March 18, 2011 2:22:44 PM

Post# of 252540
BMY/PFE—No drug recommended by the CHMP has ever been denied approval by the EU, so Apixaban is as good as approved in the EU. It has the potential to be a big enough drug to move the needle even for companies as large as BMY and PFE.

Approval for VTE prevention in the EU may help to some degree with the FDA, although BMY/PFE have not seemed confident about making headway with the FDA in this indication (#msg-58061618).

p.s. The brand name, Eliquis, is a bizarre choice with a sound dangerously close to Elevess (the dermal filler).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up